News

News and Press Releases
Advocacy | Antibiotics Adult with CF Provides Testimony at Congressional Hearing on the Impact of Antimicrobial Resistance 

Melanie Lawrence, an adult with cystic fibrosis, was selected to testify before a Senate Health, Education, Labor and Pensions subcommittee regarding the impact of antimicrobial resistance on patients who face heightened risk of infections, like those with CF.

| 3 min read
About the CF Foundation | Antibiotics | Infection Prevention and Control CF Foundation Invests Up to $4.85 Million in Aridis Pharmaceuticals for Testing of Anti-Infective

The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.

| 2 min read
Advocacy | Antibiotics | Public Policy 165 Organizations Urge Lawmakers to Advance PASTEUR Act Before Congress Ends

Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.

| 3 min read
Antibiotics | Advocacy CF Foundation Affirms Support of the Introduction of the PASTEUR Act

Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.

| 2 min read
Research | Antibiotics | About the CF Foundation CF Foundation Awards Up to $3.3M to Polyphor for Inhaled Version of Antibiotic to Treat Pseudomonas

Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.

| 3 min read
Research | Antibiotics | Our Research Approach CF Foundation Awards Up to $5.6 Million to Develop Novel Antibiotic to Fight Drug-Resistant Bacteria

The Cystic Fibrosis Foundation has awarded up to $5.6 million to Microbion Corporation to develop a novel, inhaled antibiotic to treat drug-resistant bacterial infections in people with cystic fibrosis.

| 2 min read
About the CF Foundation | Drug Pipeline | Antibiotics FDA Approves New Powder Form of CF Drug TOBI®

The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).

| 1 min read
Antibiotics New Inhaled Antibiotic Cayston Gains Rapid and Broad Acceptance – 2010 NACFC

A key focus of this year's North American Cystic Fibrosis Conference (NACFC) was the progress of the more than 30 potential new therapies moving through the CF Foundation's drug development pipeline.

| 2 min read
Antibiotics New Inhaled Antibiotic Cayston Now Available for People with CF

A new inhaled antibiotic for the treatment of cystic fibrosis called Cayston® is now available for patients through select specialty pharmacies, including the CF Services Pharmacy. 

| 2 min read
About the CF Foundation | Drug Pipeline | Antibiotics FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade

CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality

| 4 min read